S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.99%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.99%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.99%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.99%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
NASDAQ:IVA

Inventiva (IVA) Stock Forecast, Price & News

$4.26
+0.10 (+2.40%)
(As of 05:19 PM ET)
Compare
Today's Range
$4.00
$4.30
50-Day Range
$3.41
$4.44
52-Week Range
$2.22
$11.75
Volume
3,023 shs
Average Volume
62,032 shs
Market Capitalization
$220.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.33

Inventiva MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
372.7% Upside
$19.33 Price Target
Short Interest
Healthy
0.18% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.20mentions of Inventiva in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.95) to ($1.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

457th out of 975 stocks

Pharmaceutical Preparations Industry

203rd out of 456 stocks


IVA stock logo

About Inventiva (NASDAQ:IVA) Stock

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

IVA Price History

IVA Stock News Headlines

Inventiva (IVA) to Release Earnings on Thursday
Inventiva's (IVA) "Buy" Rating Reaffirmed at Roth Mkm
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease
Pre-market Movers: MURF, IFRX, NEPT, UPTD, AEHL…
Inventiva ADRs Rise 9% Following Licensing Deal
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
H.C. Wainwright Reaffirms Their Buy Rating on Inventiva (IVA)
Where Inventiva Stands With Analysts
Inventiva Rises In Morning Trade
See More Headlines
Receive IVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter.

IVA Company Calendar

Today
9/28/2023
Next Earnings (Confirmed)
9/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IVA
Fax
N/A
Employees
109
Year Founded
2011

Price Target and Rating

Average Stock Price Forecast
$19.33
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+353.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$12.83 million
Book Value
$1.14 per share

Miscellaneous

Free Float
35,192,000
Market Cap
$220.46 million
Optionable
Not Optionable
Beta
0.99

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Frederic Cren (Age 57)
    Co-Founder, CEO & Chairman
    Comp: $539.62k
  • Dr. Pierre Broqua Ph.D. (Age 61)
    Co-Founder, Chief Scientific Officer, Deputy CEO & Director
    Comp: $404.75k
  • Mr. Jean Volatier (Age 58)
    Chief Financial Officer
  • Alice Roudot-Ketelers Pharm.D.
    Chief Operating Officer
  • Mr. Eric Duranson L.L.M. (Age 49)
    Gen. Counsel
  • Ms. Nathalie Harroy (Age 56)
    Head of HR
  • Dr. Irena Konstantinova
    Head of Biology & Pharmacology
  • Dr. Michael Cooreman (Age 65)
    Chief Medical Officer
  • Mr. Jean-Paul Dutertre M.D.
    Head of Pharmacovigilance













IVA Stock - Frequently Asked Questions

Should I buy or sell Inventiva stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inventiva in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IVA shares.
View IVA analyst ratings
or view top-rated stocks.

What is Inventiva's stock price forecast for 2023?

5 brokerages have issued 12 month price objectives for Inventiva's stock. Their IVA share price forecasts range from $11.00 to $35.00. On average, they expect the company's share price to reach $19.33 in the next year. This suggests a possible upside of 353.8% from the stock's current price.
View analysts price targets for IVA
or view top-rated stocks among Wall Street analysts.

How have IVA shares performed in 2023?

Inventiva's stock was trading at $4.46 at the beginning of the year. Since then, IVA stock has decreased by 4.5% and is now trading at $4.26.
View the best growth stocks for 2023 here
.

Are investors shorting Inventiva?

Inventiva saw a decrease in short interest in September. As of September 15th, there was short interest totaling 90,900 shares, a decrease of 5.6% from the August 31st total of 96,300 shares. Based on an average trading volume of 25,200 shares, the days-to-cover ratio is currently 3.6 days.
View Inventiva's Short Interest
.

When is Inventiva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, September 28th 2023.
View our IVA earnings forecast
.

When did Inventiva IPO?

(IVA) raised $103 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 7,500,000 shares at a price of $13.68 per share. Jefferies, Stifel and Guggenheim Securities served as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers.

What is Inventiva's stock symbol?

Inventiva trades on the NASDAQ under the ticker symbol "IVA."

How do I buy shares of Inventiva?

Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inventiva's stock price today?

One share of IVA stock can currently be purchased for approximately $4.26.

How much money does Inventiva make?

Inventiva (NASDAQ:IVA) has a market capitalization of $220.46 million and generates $12.83 million in revenue each year.

How many employees does Inventiva have?

The company employs 109 workers across the globe.

How can I contact Inventiva?

Inventiva's mailing address is 50 RUE DE DIJON, DAIX I0, 21121. The official website for the company is www.inventivapharma.com. The company can be reached via phone at 33-3-80-44-75-00 or via email at finance@inventivapharma.com.

This page (NASDAQ:IVA) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -